Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis

Apoptosis

Volumn 17, Issue 1, 2012, Pages 79-89

  Henrich, Curtis J ^a,b   Thomas, Cheryl L ^a   Brooks, Alan D ^a,b   Booth, Nancy Lynn ^a,c   Lowery, Evan M ^a   Pompei, Richard J ^a   McMahon, James B ^a   Sayers, Thomas J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Spherix Inc   (United States)

Author keywords

Apoptosis; Cell morphology; Cucurbitacins; STAT3; TRAIL; TRAIL sensitizers

Indexed keywords

ACETYLCYSTEINE; BORTEZOMIB; CASPASE 8; CUCURBITACIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, RENAL CELL; CASPASE 8; CELL LINE, TUMOR; CELL SHAPE; CUCURBITACINS; HUMANS; KIDNEY NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84856727211     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-011-0652-7     Document Type: Article

References (40)

1. Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H (2010) Towards novel paradigms for cancer therapy. Oncogene 30:1-20
2. Holoch PA, Griffith TS (2009) TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625:63-72
3. Mahmood Z, Shukla Y (2010) Death receptors: targets for cancer therapy. Exp Cell Res 316:887-899
4. Gonzalvez F, Ashkenazi A (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29:4752-4765
5. Sayers TJ (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60:1173-1180
6. Ivanov VN, Bhoumik A, Ronai Z (2003) Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152-3161 (Pubitemid 36713767)
7. Rahman M, Pumphrey JG, Lipkowitz S (2009) The TRAIL to targeted therapy of breast cancer. Adv Cancer Res 103:43-73
8. Testa U (2010) TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem 110:21-34
9. Stegehuis JH, de Witt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA (2010) TRAIL receptor targeting therapies for nonsmall cell lung cancer: current status and perspectives. Drug Resist Updates 13:2-15
10. Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ (2009) A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother 58:1229-1244
11. Lee DH, Iwanski GB, Thoennissen NH (2010) Cucurbitacin: ancient compound shedding new light on cancer treatment. ScientificWorldJournal 5:413-418
12. Deng J, Grande F, Neamati N (2007) Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 7:91-107 (Pubitemid 46345511)
13. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H (2006) Targeting signaltransducer- and-activator-of- transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 1091:151-169 (Pubitemid 47092233)
14. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T (2010) Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 54: 559-565
15. Finnberg N, Klein-Szanto AJ, El-Deiry WS (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118:111-123
16. Huang S, Sinicrope FA (2010) Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 9:742-750
17. Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S, Marchisio M (2009) Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of JAK2/STAT3. Cell Res 19:1079-1089
18. Kusuba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, Eguchi K (2007) Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 47:546-555 (Pubitemid 47331746)
19. Kannappan R, Ravindran J, Prasad S, Sung B, Yadav VR, Reuter S, Chaturvedi MM, Aggarwal BB (2010) Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/ extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther 9:2196-2207
20. Lee TJ, Um HJ, Min do S, Park JW, Choi KS, Kwon TK (2009) Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 46: 1639-1649
21. Sung B, Ravindran J, Prasad S, Pandey MK, Aggarwal BB (2010) Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285:35418-35427
22. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ (2010) Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the deathinducing signaling complex. Mol Cancer Res 8:729-738
23. Li L, Cheung S-h, Evans EL, Shaw PE (2010) Modulation of gene expression and tumor cell growth by redox modification of STAT3. Cancer Res 70:8222-8232
24. Ishidorj G, Johnston JB, Gibson SB (2010) Inhibition of constitutive activation of STAT3 by cucurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther 9: 3302-3314
25. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42:588-597 (Pubitemid 41233651)
26. Hellwig CT, Kohler BF, Lehtivarjo A-K, Dussmann H, Courtney MJ, Prehn JHM, Rehm M (2008) Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cycloheximideinduced caspase activities during apoptosis initiation. J Biol Chem 283:21676-21685
27. Oberst A, Pop C, Tremblay AG, Blais V, Denault J-B, Salvesen GS, Green DR (2010) Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem 285:16632-16642
28. Pennarun B, Meijer A, de Vries EGE, Kleibeuker JH, Kruyt F, de Jong S (2010) Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 1805:123-140
29. Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6-20 (Pubitemid 36223114)
30. Yin D, Wakimoto N, Xing H, Lu D, Huynh T, Wang X, Black KL, Koeffler HP (2008) Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 123:1364-1375
31. Haritunians T, Gueller S, Zhang L, Badr R, Yin D, Xing H, Fung MC, Koeffler HP (2008) Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 32:1366-1373
32. Phipps LE, Hino S, Muschel RJ (2011) Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis. Mol Cancer Res 9:249-258
33. Afifi MS, Ross SA, ElSohly MA, Naeem ZE, Halaweish FT (1999) Cucurbitacins of Cucumis prophetarum. J Chem Ecol 25:847-859
34. Bartalis J, Halaweish FT (2005) Relationship between cucurbitacins reversed-phase high-performance liquid chromatography hydrophobicity index and basal cytotoxicity on HepG2 cells. J Chromatogr B 818:159-166 (Pubitemid 40331820)
35. van Dang G, Rode BM, Stuppner H (1994) Quantitative electronic structure-activity relationship (QESAR) of natural cytotoxic compounds: maytansinoids, quassinoids and cucurbitacins. Eur J Pharm Sci 2:331-350
36. Sun J, Baskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM (2005) Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24:3236-3245 (Pubitemid 40695105)
37. Gamero AM, Young HA, Wiltrout RH (2004) Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 5:111-112 (Pubitemid 38283795)
38. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Day S, Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171:59-76
39. Boykin C, Zhang G, Chen YH, Zhang RW, Fan XE, Yang WM, Lu Q (2011) Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting surviving independent of JAK2/STAT3 phosphorylation. Br J Cancer 104:781-789
40. Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH, Koeffler HP (2010) Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 160:998-1007